Novartis Partners with SHYFT
SHYFT Analytics announced that Novartis selected its Intelligent Platform for Life Sciences to support the commercialization of therapies in Europe.
Novartis will use the following SHYFT solutions:
- STRATA Data Platform to aggregate and manage a growing number of third party and proprietary commercial data sources
- LUMEN Insights Platform to deliver intuitively-designed analytics to drive the “next-best-actions” for commercial teams
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Novo Nordisk, The United Laboratories Ink Exclusive License Agreement for Triple Receptor Agonist
March 25th 2025Under terms of the license agreement, Novo Nordisk will acquire the rights to develop and commercialize UBT251 outside of China for obesity and type 2 diabetes for an upfront payment of $200 million.
